Evidence map›Paper›PMID 34001907›Full record

ReviewNPJ Regenerative medicine2021

Running the full human developmental clock in interspecies chimeras using alternative human stem cells with expanded embryonic potential.

Justin Thomas, Ludovic Zimmerlin, Jeffrey S Huo, Michael Considine, Leslie Cope, Elias T Zambidis

Open access · goldAbstract readReview
In one paragraph

Review in NPJ Regenerative medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. In Vivo CaBiomedicines · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Justin ThomasInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ludovic ZimmerlinInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeffrey S HuoInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael ConsidineSidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Leslie CopeSidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elias T ZambidisInstitute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. ezambid1@jhmi.edu.ORCID http://orcid.org/0000-0001-5452-254X
Johns Hopkins University · US

Funding

Embryonic vascular stem-progenitors for treatment of ischemic retinopathiesR01EY032113 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2021 to 2024
$2.0M
Pluripotent Stem Cell Vascular Therapies for Ischemic RetinopathiesR01EY023962 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2014 to 2018
$1.8M
Functional Vascular Progenitors from Naive Human iPSCR01HD082098 · NICHD · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2015 to 2019
$1.7M
Transcriptional and Epigenetic Regulation of HSC Generated from iPS and ESCR03HL096220 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI FRIEDMAN, ALAN D, ZAMBIDIS, ELIAS T. · 2009 to 2009
$41k
NEI NIH HHS R01 EY023962NEI NIH HHS R01 EY032113NHLBI NIH HHS R03 HL096220NICHD NIH HHS R01 HD082098
6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs) can generate specialized cell lineages that have great potential for regenerative therapies and disease modeling. However, the developmental stage of the lineages generated from conventional hPSC cultures in vitro are embryonic in phenotype, and may not possess the cellular maturity necessary for corrective regenerative function in vivo in adult recipients. Here, we present the scientific evidence for how adult human tissues could generate human-animal interspecific chimeras to solve this problem. First, we review the phenotypes of the embryonic lineages differentiated from conventional hPSC in vitro and through organoid technologies and compare their functional relevance to the tissues generated during normal human in utero fetal and adult development. We hypothesize that the developmental incongruence of embryo-stage hPSC-differentiated cells transplanted into a recipient adult host niche is an important mechanism ultimately limiting their utility in cell therapies and adult disease modeling. We propose that this developmental obstacle can be overcome with optimized interspecies chimeras that permit the generation of adult-staged, patient-specific whole organs within animal hosts with human-compatible gestational time-frames. We suggest that achieving this goal may ultimately have to await the derivation of alternative, primitive totipotent-like stem cells with improved embryonic chimera capacities. We review the scientific challenges of deriving alternative human stem cell states with expanded embryonic potential, outline a path forward for conducting this emerging research with appropriate ethical and regulatory oversight, and defend the case of why current federal funding restrictions on this important category of biomedical research should be liberalized.

Identifiers

PMID34001907
PMCPMC8128894
OpenAlexW3163781665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.